We sought to determine whether valdecoxib is as effective as diclofenac in treating acute ankle sprain. Patients (n = 202) with acute first-and second-degree ankle sprain were randomized to valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2-7) or diclofenac (75 mg twice daily). The primary efficacy end-point was the Patient's Assessment of Ankle Pain visual analogue scale (VAS, 0-100 mm) value on day 4. Valdecoxib was as efficacious as diclofenac in treating the signs and symptoms of acute ankle sprain. The mean VAS reduction in ankle pain on day 4 was not different between groups; the two-sided 95% confidence interval for the between-group difference was within the pre-specified limit for non-inferiority (10 mm). There were no significant differences between groups for all secondary efficacy end-points. The two treatments were similarly effective and well tolerated for treatment of acute ankle sprain.
BraunBL: Effects of ankle sprain in a general clinic population 6 to 18 months after medical evaluation. Arch Fam Med1999; 8: 143–148.
3.
VerhagenRAde KeizerGvan DijkCN: Long-term follow-up of inversion trauma of the ankle. Arch Orthop Trauma Surg1995; 114: 92–96.
4.
YeungMSChanKMSoCHYuanWY: An epidemiological survey on ankle sprain. Br J Sports Med1994; 28: 112–116.
5.
ZhangYShafferAPortanovaJSeibertKIsaksonPC: Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther1997; 283: 1069–1075.
6.
Ogilvie-HarrisDJGilbartM: Treatment modalities for soft tissue injuries of the ankle: A critical review. Clin J Sport Med1995; 5: 175–186.
7.
Bouchier-HayesTA: Naproxen sodium and piroxicam in acute musculo-skeletal disorders. Br J Sports Med1984; 18: 80–83.
8.
DuncanJJFarrJE: Comparison of diclofenac sodium and aspirin in the treatment of acute sports injuries. Am J Sports Med1988; 16: 656–659.
9.
EkmanEFFiechtnerJJLevySFortJG: Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: A multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop2002; 31: 445–451.
10.
EkmanEFRuoffGKuehlKRalphLHormbreyPFiechtnerJI: The COX-2 specific inhibitor valdecoxib versus tramadol in acute ankle sprain: A multicenter, randomized, controlled trial. Am J Sports Med2006; 34: 945–955.
11.
HeereLP: Piroxicam in acute musculoskeletal disorders and sport injuries. Eur J Rheumatol Inflamm1987; 8: 60–64.
12.
PetrellaREkmanEFSchullerRFortJG: Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: Results of a double-blind, randomized controlled trial. Clin J Sport Med2004; 14: 225–231.
13.
SlatyerMAHensleyMJLopertR: A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Am J Sports Med1997; 25: 544–553.
14.
GoldsteinJLEisenGMAgrawalNStensonWFKentJDVerburgKM: Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther2004; 20: 527–538.
15.
GoldsteinJLKivitzAJVerburgKMReckerDPPalmerRCKentJD: A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther2003; 18: 125–132.
16.
HarrisSIKussMHubbardRCGoldsteinJL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther2001; 23: 1422–1428.
17.
PavelkaKReckerDPVerburgKM: Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial. Rheumatology (Oxford)2003; 42: 1207–1215.
18.
SikesDHAgrawalNMZhaoWWKentJDReckerDPVerburgKM: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol2002; 14: 1101–1111.
19.
GreenDDaviesROHolmesGIKohlHLeeRBReynoldsN: Effects of diflunisal on platelet function and fecal blood loss. Clin Pharmacol Ther1981; 30: 378–384.
20.
LeesePTHubbardRCKarimAIsaksonPCYuSSGeisGS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol2000; 40: 124–132.
21.
LeesePTReckerDPKentJD: The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: Results of a randomized controlled trial. J Clin Pharmacol2003; 43: 504–513.
22.
LeesePTTalwalkerSKentJDReckerDP: Valdecoxib does not impair platelet function. Am J Emerg Med2002; 20: 275–281.
23.
BensenWWeaverAEspinozaLZhaoWWRileyWPaperielloB: Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford)2002; 41: 1008–1016.
24.
KivitzAEisenGZhaoWWBevirtTReckerDP: Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract2002; 51: 530–537.
25.
MakarowskiWZhaoWWBevirtTReckerDP: Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage2002; 10: 290–296.
26.
CamuFBeecherTReckerDPVerburgKM: Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther2002; 9: 43–51.
27.
DanielsSEDesjardinsPJTalwalkerSReckerDPVerburgKM: The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc2002; 133: 611–621.
28.
FrickeJVarkalisJZwillichSAdlerRForesterEReckerDP: Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther2002; 9: 89–97.
29.
ReynoldsLWHooRKBrillRJNorthJReckerDPVerburgKM: The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage2003; 25: 133–141.
30.
SkoutakisVACarterCAMickleTRSmithVHArkinCRAlissandratosJ: Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm1988; 22: 850–859.
ToddPASorkinEM: Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs1988; 35: 244–285.
33.
MoranM: An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprains. Curr Med Res Opin1990; 12: 268–274.
34.
MoranM: Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res1991; 19: 121–130.
35.
VerstraetenABakshiR: Diclofenac potassium for the treatment of traumatic joint distortions: An open multicentre study. J Int Med Res1991; 19: 165–170.
36.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). June 1996. Available at: www.ich.org/MediaServer.jser?@_ID=482&@_MODE=GLB (last accessed 23 May 2006).
37.
ForouzanfarTWeberWEKemlerMvan KleefM: What is a meaningful pain reduction in patients with complex regional pain syndrome type 1?. Clin J Pain2003; 19: 281–285.
38.
JensenMPChenCBruggerAM: Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J Pain2003; 4: 407–414.
JenkinsJKSeligmanPJ: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Food and Drug Administration. Available at: www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf (last accessed 1 September 2006).
41.
MahlerPMahlerFDuruzHRamazzinaMLiguoriVMautoneG: Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. Drugs Exp Clin Res2003; 29: 45–52.
